Literature DB >> 30885969

The impact of pharmaceutical rebates on patients' drug expenditures.

K Ally Memedovich1, Braden Manns1, Reed Beall1, Aidan Hollis1, Fiona Clement2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30885969      PMCID： PMC6422779          DOI： 10.1503/cmaj.181041

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.

Authors:  Jamie R Daw; Steven G Morgan
Journal:  Health Policy       Date:  2011-10-05       Impact factor: 2.980

2.  International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies.

Authors:  Steven Morgan; Jamie Daw; Paige Thomson
Journal:  Health Aff (Millwood)       Date:  2013-04       Impact factor: 6.301

3.  Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.

Authors:  David J T Campbell; Braden J Manns; Lesley J J Soril; Fiona Clement
Journal:  CMAJ Open       Date:  2017-11-22

4.  Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.

Authors:  Stacie B Dusetzina; Rena M Conti; Nancy L Yu; Peter B Bach
Journal:  JAMA Intern Med       Date:  2017-08-01       Impact factor: 21.873
  4 in total
  1 in total

1.  Antihypertensive Prescribing for Uncomplicated, Incident Hypertension: Opportunities for Cost Savings.

Authors:  Amity E Quinn; Paul E Ronksley; Lauren Bresee; Flora Au; James Wick; Alexander A Leung; Kerry A McBrien; Braden J Manns; Reed F Beall
Journal:  CJC Open       Date:  2021-01-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.